Ro 32-7315 | CAS#219613-02-2 | ADAM17 inhibitor

MedKoo Cat#: 563302 | Name: Ro 32-7315

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ro 32-7315 is an ADAM17-selective inhibitor.

Chemical Structure

Ro 32-7315

CAS#219613-02-2

Theoretical Analysis

MedKoo Cat#: 563302

Name: Ro 32-7315

CAS#: 219613-02-2

Chemical Formula: C22H35N3O5S

Exact Mass: 453.2297

Molecular Weight: 453.59

Elemental Analysis: C, 58.25; H, 7.78; N, 9.26; O, 17.64; S, 7.07

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Ro 32-7315; Ro 327315; Ro-327315; Ro 32 7315; Ro327315;

IUPAC/Chemical Name

(2S,3R)-2-cinnamyl-N-hydroxy-3-(2-isobutyl-2-(methylsulfonyl)hydrazine-1-carbonyl)-5-methylhexanamide

InChi Key

BACZSFOSMGICGM-WQEUXLNQSA-N

InChi Code

InChI=1S/C22H35N3O5S/c1-16(2)14-20(21(26)23-25(15-17(3)4)31(5,29)30)19(22(27)24-28)13-9-12-18-10-7-6-8-11-18/h6-12,16-17,19-20,28H,13-15H2,1-5H3,(H,23,26)(H,24,27)/b12-9+/t19-,20+/m0/s1

SMILES Code

ONC([C@H]([C@@H](CC(C)C)C(NN(S(=O)(C)=O)CC(C)C)=O)C/C=C/C1=CC=CC=C1)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 453.59 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Liechti FD, Grandgirard D, Leppert D, Leib SL. Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infect Immun. 2014 Apr;82(4):1710-8. doi: 10.1128/IAI.00073-14. Epub 2014 Feb 3. Erratum in: Infect Immun. 2014 Oct;82(10):4435. PubMed PMID: 24491581; PubMed Central PMCID: PMC3993388. 2: Moreira-Tabaka H, Peluso J, Vonesch JL, Hentsch D, Kessler P, Reimund JM, Dumont S, Muller CD. Unlike for human monocytes after LPS activation, release of TNF-α by THP-1 cells is produced by a TACE catalytically different from constitutive TACE. PLoS One. 2012;7(3):e34184. doi: 10.1371/journal.pone.0034184. Epub 2012 Mar 30. PubMed PMID: 22479555; PubMed Central PMCID: PMC3316627. 3: Vahdat AM, Reiners KS, Simhadri VL, Eichenauer DA, Böll B, Chalaris A, Simhadri VR, Wiegmann K, Krell HW, Rose-John S, Engert A, von Strandmann EP, Hansen HP. TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species. Leukemia. 2010 Jan;24(1):51-7. doi: 10.1038/leu.2009.230. Epub 2009 Nov 5. PubMed PMID: 19890373. 4: Kruse MN, Becker C, Lottaz D, Köhler D, Yiallouros I, Krell HW, Sterchi EE, Stöcker W. Human meprin alpha and beta homo-oligomers: cleavage of basement membrane proteins and sensitivity to metalloprotease inhibitors. Biochem J. 2004 Mar 1;378(Pt 2):383-9. PubMed PMID: 14594449; PubMed Central PMCID: PMC1223953. 5: Beck G, Bottomley G, Bradshaw D, Brewster M, Broadhurst M, Devos R, Hill C, Johnson W, Kim HJ, Kirtland S, Kneer J, Lad N, Mackenzie R, Martin R, Nixon J, Price G, Rodwell A, Rose F, Tang JP, Walter DS, Wilson K, Worth E. (E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2'-isobutyl-2'-(methanesulf onyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-alpha convertase. J Pharmacol Exp Ther. 2002 Jul;302(1):390-6. PubMed PMID: 12065742.